San Diego, CA -- (SBWIRE) -- 11/11/2014 -- An investigation on behalf of current long-term investors in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Bio-Rad Laboratories.

Investors who purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) and currently hold any of those NYSE:BIO shares have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Bio-Rad Laboratories officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Bio-Rad Laboratories, Inc. reported that its Total Revenue rose from over $2.06 billion in 2012 to over $2.13 billion in 2013 while its respective Net Income declined from $165.48 million to $77.79 million.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) grew from $90.03 per share in late 2011 to as high as $133.73 per share in February 2014.

Since then NYSE:BIO shares lost significant value.

On November 4, 2014, Bio-Rad Laboratories, Inc. reported its third quarter 2014 financial results. Among other things, Bio-Rad Laboratories, Inc. said that in May 2010 it disclosed to the U.S. Department of Justice (“DOJ”) and the Securities and Exchange Commission (“SEC”) certain likely or potential violations of the United States Foreign Corrupt Practices Act (“FCPA”) and that effective November 3, 2014, it entered into a non-prosecution agreement with the DOJ and consented to the entry of an Order by the SEC (SEC Order), which actions resolve both the DOJ and the SEC investigations.

Bio-Rad Laboratories, Inc. said that the non-prosecution agreement with the DOJ concerns violations of the FCPA’s books and records and internal control provisions related to Russia during 2005-2010. And that pursuant to the non-prosecution agreement Bio-Rad Laboratories agreed to pay a penalty of $14.4 million and to certain compliance, reporting and cooperation obligations, and the DOJ agreed that it will not criminally prosecute Bio-Rad Laboratories for any crimes related to conduct disclosed to the DOJ, provided that Bio-Rad Laboratories performs its obligations under the non-prosecution agreement for two years.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) declined on November 5, 2014, to as low as $102.71 per share.

Those who purchased shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com